Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Peijia Medical Ltd. ( (HK:9996) ) has shared an update.
Peijia Medical Ltd. has announced the successful completion of the first patient implant in the Global Clinical Study of its MonarQ TTVR® system, an innovative device designed to treat Tricuspid Regurgitation. This marks a significant milestone for the company, as it officially launches the global study and advances its pipeline development in this area, potentially impacting its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Ltd. is a company incorporated in the Cayman Islands, operating in the medical technology industry. It focuses on developing innovative medical devices, particularly in the field of cardiac care, with a market focus on treating conditions like Tricuspid Regurgitation.
YTD Price Performance: 77.14%
Average Trading Volume: 1,770,738
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.71B
See more data about 9996 stock on TipRanks’ Stock Analysis page.